Talquetamab, a bispecific antibody therapy, was announced to be successful in 73% of patients. This past weekend, the results of the Phase I trial were reported in NEJM and the results of the Phase II trial were announced at the ASH meeting being held in New Orleans. The participants had all been previously treated with different therapies, suggesting talquetamab could offer new hope for patients with multiple myeloma.